[Surgery for thymomas and thymic carcinomas; treatment results in terms of WHO histologic typing, Masaoka staging system, and p53 expression].
Forty thymomas and thymic carcinomas were classified in terms of WHO histologic typing, Masaoka staging system, and p53 expression. In WHO histologic typing, type A, AB, B1, B2, B3, and C were 1, 10, 16, 5, 4, and 4 cases, respectively. In Masaoka staging system, I, II, III, and IV were 15, 9, 10, and 6 cases, respectively. Thirteen thymomas exhibited positive p53 expression and 27 did not. Type A and AB thymomas had more favorite prognosis than type B3 and C thymomas, and prognosis of type B1 and B2 was middle. Staging by the Masaoka system also correlated with survival rates. Patients who had p53-negative thymomas survived longer than those who had p53-positive thymomas. A treatment strategy for thymomas and thymic carcinomas should be made on the basis of WHO histologic typing, Masaoka staging system, and p53 expression.
Yamazaki
K
K
Department of Surgery, Asahikawa Medical University, Asahikawa, Japan.
Kitada
M
M
Sasaki
K
K
Koshiko
S
S
Hirasawa
M
M
Ozawa
K
K
Kajiura
Y
Y
Sasajima
T
T
Miyokawa
N
N
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate; D013934:Thymectomy; D013945:Thymoma / Q000145:classification / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D013953:Thymus Neoplasms / Q000145:classification / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis*
D016159:Tumor Suppressor Protein p53